VentiRx Pharmaceuticals Inc. announced March 6 that it completed $26.6 million in Series A financing to be used to create a portfolio of drug candidates.
San Diego-based VentiRx develops medicines to treat cancer and infectious, respiratory and autoimmune diseases.
Seattle-based Frazier Healthcare Venture, Chicago-based Arch Venture Partners and Princeton, N.J.-based Domain Associates led the round of financing.
Company representatives were appointed to the VentiRx board of directors in connection with the financing.
, Andy Killion